<SEC-DOCUMENT>0001027035-26-000006.txt : 20260309
<SEC-HEADER>0001027035-26-000006.hdr.sgml : 20260309
<ACCEPTANCE-DATETIME>20260309181205
ACCESSION NUMBER:		0001027035-26-000006
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250304
FILED AS OF DATE:		20260309
DATE AS OF CHANGE:		20260309

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			CHILDS JOHN W
		CENTRAL INDEX KEY:			0001027035
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41477
		FILM NUMBER:		26736503

	MAIL ADDRESS:	
		STREET 1:		111 HUNTINGTON AVENUE
		STREET 2:		SUITE 2900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02199

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biohaven Ltd.
		CENTRAL INDEX KEY:			0001935979
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203-404-0410

	MAIL ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Biohaven Research Ltd.
		DATE OF NAME CHANGE:	20220629
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>wk-form4a_1773094322.xml
<DESCRIPTION>FORM 4/A
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2025-03-04</periodOfReport>

    <dateOfOriginalSubmission>2025-03-05</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001935979</issuerCik>
        <issuerName>Biohaven Ltd.</issuerName>
        <issuerTradingSymbol>BHVN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001027035</rptOwnerCik>
            <rptOwnerName>CHILDS JOHN W</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BIOHAVEN LTD.</rptOwnerStreet1>
            <rptOwnerStreet2>215 CHURCH STREET</rptOwnerStreet2>
            <rptOwnerCity>NEW HAVEN</rptOwnerCity>
            <rptOwnerState>CT</rptOwnerState>
            <rptOwnerZipCode>06510</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2025-03-04</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>28400</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>30.4266</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2323971</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By John W Childs 2013 Revocable Trust</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Shares</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>73170</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By 2013 Charitable Remainder Trust</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on March 5, 2025 (the &quot;Original Form 4&quot;). The Original Form 4 inadvertently misstated that 3,400 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and 25,000 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 28,400 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust, and no Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ George Clark, Attorney-in-Fact</signatureName>
        <signatureDate>2026-03-09</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
